HomeCompareCNVVF vs ABBV

CNVVF vs ABBV: Dividend Comparison 2026

CNVVF yields 2.66% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CNVVF wins by $233.22M in total portfolio value· pulled ahead in Year 3
10 years
CNVVF
CNVVF
● Live price
2.66%
Share price
$2.63
Annual div
$0.07
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$233.32M
Annual income
$217,615,015.11
Full CNVVF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — CNVVF vs ABBV

📍 CNVVF pulled ahead of the other in Year 3

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCNVVFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CNVVF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CNVVF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CNVVF
Annual income on $10K today (after 15% tax)
$226.24/yr
After 10yr DRIP, annual income (after tax)
$184,972,762.84/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, CNVVF beats the other by $184,951,706.84/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CNVVF + ABBV for your $10,000?

CNVVF: 50%ABBV: 50%
100% ABBV50/50100% CNVVF
Portfolio after 10yr
$116.71M
Annual income
$108,819,893.43/yr
Blended yield
93.24%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

CNVVF
No analyst data
Altman Z
3.9
Piotroski
7/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CNVVF buys
0
ABBV buys
0
No recent congressional trades found for CNVVF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCNVVFABBV
Forward yield2.66%3.06%
Annual dividend / share$0.07$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%40.6%
Portfolio after 10y$233.32M$102.3K
Annual income after 10y$217,615,015.11$24,771.77
Total dividends collected$232.13M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: CNVVF vs ABBV ($10,000, DRIP)

YearCNVVF PortfolioCNVVF Income/yrABBV PortfolioABBV Income/yrGap
1$11,232$532.32$11,550$430.00$318.00ABBV
2$13,136$1,117.60$13,472$627.96$336.00ABBV
3← crossover$16,499$2,443.06$15,906$926.08+$593.00CNVVF
4$23,389$5,735.39$19,071$1,382.55+$4.3KCNVVF
5$40,224$15,197.43$23,302$2,095.81+$16.9KCNVVF
6$91,892$48,852.40$29,150$3,237.93+$62.7KCNVVF
7$306,930$208,605.82$37,536$5,121.41+$269.4KCNVVF
8$1,630,788$1,302,372.58$50,079$8,338.38+$1.58MCNVVF
9$14,679,140$12,934,196.98$69,753$14,065.80+$14.61MCNVVF
10$233,321,695$217,615,015.11$102,337$24,771.77+$233.22MCNVVF

CNVVF vs ABBV: Complete Analysis 2026

CNVVFStock

ConvaTec Group Plc develops, manufactures, and markets medical products and technologies worldwide. It offers advanced wound dressings and skin care products for the management of acute and chronic wounds resulting from various conditions, such as diabetes, immobility, and venous disease, as well as from traumatic injury, burns, invasive surgery, and other causes. The company also provides devices, accessories, and services for people with a stoma resulting from colorectal cancer, inflammatory bowel disease, bladder cancer, obesity, and other causes. In addition, it offers continence and critical care products, including intermittent urinary catheters; and products for people with urinary continence issues related to spinal cord injuries, multiple sclerosis, spina bifida, and other urological disorders, as well as devices and products used in intensive care units and hospital settings. Further, the company provides advanced systems for managing acute fecal incontinence, as well as for monitoring urine production output and intra-abdominal pressure; and various disposable medical devices, such as wound drainage systems, urine collection bags and catheters, airway management and oxygen/aerosol therapy devices, suction handles and tubes, gastroenterology tubes, and securement devices. Additionally, it offers disposable infusion sets to manufacturers of insulin pumps for diabetes, as well as similar pumps that are used in continuous infusion treatments for other conditions; and various products to hospital and home healthcare markets. The company sells its products to pharmacies, hospitals, and other acute and post-acute healthcare service providers directly or through distributors and wholesalers. It serves a range of customers, including healthcare providers, patients, and manufacturers. The company was founded in 1978 and is headquartered in Reading, the United Kingdom.

Full CNVVF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this CNVVF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CNVVF vs SCHDCNVVF vs JEPICNVVF vs OCNVVF vs KOCNVVF vs MAINCNVVF vs JNJCNVVF vs MRKCNVVF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.